Table 2.

Clinical trials evaluating new approaches focused on early cancer detection through screening

NCT	Sponsor	Trial name	Estimated enrollment	Biomarker	Condition	Age eligibility (years)	Status
NCT05366881	Adela	CAMPERR	7,000	cfDNA	MCED	≥40	Recruiting
NCT04972201	Burning Rock	PROMISE	2,305	cfNA	MCED	40–75	Recruiting
NCT03869814	ClearNote Health	MT1410	6,500	5-hmC ctDNA	MCED	45–75	Recruiting
NCT04825834	DELFI Diagnostics	L101	2,500	ctDNA	Lung cancer	≥50	Recruiting
NCT05306288	DELFI Diagnostics	CASCADE	15,000	ctDNA	Lung cancer	≥50	Recruiting
NCT04144751	Exact Sciences	Blue-C	24,000	Blood-based	Colorectal cancer	≥40	Active, not recruiting
NCT04369053	Freenome	Preempt	25,000	ctDNA	Colorectal cancer	45–84	Active, not recruiting
NCT05516927	Freenome	Sanderson Study	8,000	Multiomics	MCED	≥30	Recruiting
NCT05227261	Gene Solutions	K-DETEK	3,000	ctDNA	Lung, breast, liver, colorectal, and gastric cancers	≥40	Recruiting
ISRCTN10226380	Grail	SYMPLIFY	6,238	cfDNA	MCED in symptomatic individuals	≥18	Completed
NCT04241796	Grail	Pathfinder	6,662	ctDNA	MCED	≥50	Completed
NCT03085888	Grail	Strive	99,481	cfNA	MCED	≥18	Active, not recruiting
NCT03934866	Grail/UCL	Summit	13,035	cfNA	Lung cancer	55–77	Active, not recruiting
NCT03774758	Guardant Health	17–22915	590	ctDNA	Lung cancer	≥40	Recruiting
NCT04136002	Guardant Health	Eclipse	20,000	ctDNA	Colorectal cancer	45–84	Recruiting
NCT05181826	Helio Health	ELITE	1,200	ctDNA	Cancer-free, benign, cancer	≥18	Recruiting
NCT05199259	Helio Health	Liver-1	1,200	ctDNA	Hepatocellular carcinoma	≥18	Recruiting
NCT03694600	Helio Health	CLiMB	1,600	cfDNA	Liver cirrhosis, hepatocellular carcinoma	21–84	Recruiting
NCT05432128	Singlera Genomics	2019YFC1315803	600	ctDNA	Lung cancer	18–75	Recruiting
NCT05485077	Singlera Genomics	KYS-2022007	18,000	cfDNA	Colorectal cancer	≥40	Recruiting

cfDNA, cell-free DNA; cfNA, cell-free nucleic acids; ctDNA, circulating tumor-derived DNA; MCED, multi-cancer early detection.